Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Crisugabalin in Peripheral Neuralgia
NCT05890053Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crisugabalin besilate in Peripheral neuropathic pain, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Feb 2022; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT05890053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890053.